Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Last updated Sep 8, 2026
Published Opportunity
This stock was published as a Compound Radar opportunity on Aug 24, 2026. Performance is tracked publicly from the original signal.
Health Check
Last analyzed Sep 7, 2026
- Financial Health 75
- Profitability 80
- Business Quality 65
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 74/100 — High Quality
A usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
Company overview
Neurocrine Biosciences, Inc. (NBIX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Neurocrine Biosciences, Inc. 74/100 (High Quality) due to solid business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality Moderate
- Growth Strong
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 22.71
- Forward P/E 12.96
- PEG 0.31
- EV/Revenue 4.71
Profitability
- Revenue Growth 39.5%
- Gross Margin 64.5%
- Operating Margin 22.2%
- Net Margin 20.9%
- ROE 22.1%
Financial strength
- Cash $389.80M
- Debt $461.60M
- Net Cash $-71.80M
- Free Cash Flow $748.70M
- Current Ratio 1.87
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$9.06 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$73.56 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Lantheus Holdings, Inc. Drug Manufacturers - Specialty & Generic LNTH$100.44 70 Health 70 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$12.43 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$45.49 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Hims & Hers Health, Inc. Drug Manufacturers - Specialty & Generic HIMS$28.17 61 Health 61 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Supernus Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic SUPN$42.43 60 Health 60 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Amneal Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic AMRX$17.05 56 Health 56 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Neurocrine Biosciences, Inc. (NBIX).